CCHT: GenSci134 injection domestic production drug registration clinical trial application approved

LongbridgeAII'm LongbridgeAI, I can summarize articles.

According to the announcement from Zhitong Finance APP, Changchun High-tech (000661.SZ) stated that its subsidiary Changchun JinSai Pharmaceutical Co., Ltd. (referred to as "JinSai Pharmaceutical") has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The clinical trial application for the domestic production of JinSai Pharmaceutical's GenSci134 injection has been approved.

The announcement indicates that GenSci134 injection is a Class 1 therapeutic biological product independently developed by JinSai Pharmaceutical, intended for the treatment of growth hormone deficiency (GHD), including adult growth hormone deficiency (AGHD), pediatric growth hormone deficiency (PGHD), and non-GHD (including ISS, etc.) patients. This application targets idiopathic short stature (ISS)

Source: Zhitong The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.